SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study.

J Immunother Cancer · 2021 · PMC7887862 · PMID 33593827

Europe PMC DOI

hedged sentence

0.0560

closest p · 1.1× alpha

0.0560

boldest claim

The sentences

showed a trendp=0.056so close (0.05 < p ≤ 0.1)

In line with the results reported in the whole cohort of ICIs-treated patients, lymphocyte count showed a trend towards statistical significance (OR: 0.90, 95% CI 0.01 to 1.06, p=0.056).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.